Perimenopause, encompassing the period of progressive menstrual irregularity preceding a woman's final menstrual cycle and extending 12 months thereafter, is associated with an acceleration in atherosclerotic cardiovascular disease (CVD) risk, attributable in part to redistribution of body fat. During perimenopause, even in the context of minimal-to-modest weight gain, women experience an expansion of visceral adipose tissue. Concomitantly, women often experience a reduction in gluteofemoral subcutaneous adipose tissue. This pattern of fat redistribution is associated with a greater prevalence of CVD risk factors and a higher incidence of CVD events. Here we present a case of disproportionate weight gain and fat redistribution in a woman newly initiating a long-acting injectable antipsychotic medication with mild-to-moderate obesogenic effects during perimenopause.
Keywords: Cardiometabolic risk, Fat redistribution, Obesogenic medication, Perimenopause, Visceral adipose tissue, Weight gain
American journal of preventive cardiology
Journal Article
English
41567597
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.